Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Dbv Technologies ADR (NQ: DBVT )

0.7612 -0.0172 (-2.21%)
Streaming Delayed Price Updated: 3:59 PM EDT, Nov 1, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 59,687
Open 0.7700
Bid (Size) 0.7500 (1)
Ask (Size) 0.7898 (2)
Prev. Close 0.7784
Today's Range 0.7500 - 0.7962
52wk Range 0.5024 - 2.140
Shares Outstanding 55,096,537
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Tesla To Rally More Than 24%? Here Are 10 Top Analyst Forecasts For Thursday
Via Benzinga
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Via Benzinga

Performance

YTD
-59.82%
-59.82%
1 Month
+8.74%
+8.74%
3 Month
-17.68%
-17.68%
6 Month
-43.19%
-43.19%
1 Year
-61.94%
-61.94%

More News

Read More
Why Tesla Shares Are Trading Higher By Around 11%; Here Are 20 Stocks Moving Premarket
Via Benzinga
Healthcare and Biotech Stocks to Watch: MODD, CRDL, DBVT, VRAX
Via AB Newswire
Topics Intellectual Property
Exposures Intellectual Property
12 Health Care Stocks Moving In Wednesday's After-Market Session
Via Benzinga
Penny Stock DBV Technologies Advances Viaskin Peanut Allergy Patch With FDA Approval Pathway
Via Benzinga
Exposures Product Safety
12 Health Care Stocks Moving In Wednesday's Intraday Session
Via Benzinga
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Via Benzinga
Why Stride Shares Are Trading Higher By Over 24%; Here Are 20 Stocks Moving Premarket
Via Benzinga
DBV Announces Positive Regulatory Updates for the Viaskin® Peanut Patch in the United States and Europe
From DBV Technologies S.A.
Via GlobeNewswire
DBV Technologies to Participate in Upcoming ACAAI 2024 Congress
From DBV Technologies S.A.
Via GlobeNewswire
Information regarding the total number of voting rights and total number of shares of the Company as of September 30, 2024
From DBV Technologies S.A.
Via GlobeNewswire
DBV Technologies Completes Screening for the VITESSE Phase 3 Clinical Trial
From DBV Technologies S.A.
Via GlobeNewswire
DBV Technologies to Participate in the H.C. Wainwright 26th Annual Global Investment Conference
From DBV Technologies S.A.
Via GlobeNewswire
Information regarding the total number of voting rights and total number of shares of the Company as of July 31, 2024
From DBV Technologies S.A.
Via GlobeNewswire
DBVT Stock Earnings: DBV Technologies Beats EPS, Misses Revenue for Q2 2024
Via InvestorPlace
DBV Technologies Announces Filing of 2024 Half-Year Report ― Conditions for Accessing or Consulting the Report
From DBV Technologies S.A.
Via GlobeNewswire
DBV Technologies Provides Updates on the Viaskin Peanut Program in Children and Toddlers and Reports Second Quarter and Half-Year 2024 Financial Results
From DBV Technologies S.A.
Via GlobeNewswire
DBV Technologies to Report Second Quarter 2024 Financial Results and Business Update on July 30, 2024
From DBV Technologies S.A.
Via GlobeNewswire
Half-Year Report on the DBV Technologies Liquidity Contract with ODDO BHF
From DBV Technologies S.A.
Via GlobeNewswire
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Via Benzinga
DBV Technologies to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference
From DBV Technologies S.A.
Via GlobeNewswire
Information regarding the total number of voting rights and total number of shares of the Company as of May 31, 2024
From DBV Technologies S.A.
Via GlobeNewswire
DBV Technologies Announces Plan to Implement ADS Ratio Change
From DBV Technologies S.A.
Via GlobeNewswire
DBV Technologies to Participate in Upcoming EAACI 2024 Congress
From DBV Technologies S.A.
Via GlobeNewswire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.